| __timestamp | Dyne Therapeutics, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 3004000 |
| Thursday, January 1, 2015 | 2028000000 | 26972000 |
| Friday, January 1, 2016 | 2281000000 | 58187000 |
| Sunday, January 1, 2017 | 2932000000 | 79479000 |
| Monday, January 1, 2018 | 24000 | 94123000 |
| Tuesday, January 1, 2019 | 271000 | 114249000 |
| Wednesday, January 1, 2020 | 700000 | 131328000 |
| Friday, January 1, 2021 | 1088000 | 150991000 |
| Saturday, January 1, 2022 | 3345000 | 206997000 |
| Sunday, January 1, 2023 | 2461000 | 255000000 |
| Monday, January 1, 2024 | 312068000 |
Cracking the code
In the ever-evolving landscape of biotechnology, understanding cost efficiency is crucial. Incyte Corporation and Dyne Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Incyte Corporation has demonstrated a steady increase in cost of revenue, growing from approximately $3 million to $255 million, reflecting a consistent upward trend. This represents an impressive growth rate of over 8,400%.
Conversely, Dyne Therapeutics, Inc. experienced a volatile journey. Starting with a staggering $1.145 billion in 2014, their cost of revenue plummeted to just $24,000 in 2018, before stabilizing around $2.5 million in 2023. This dramatic fluctuation highlights the challenges and unpredictability in the biotech sector.
These insights underscore the importance of strategic financial management in achieving sustainable growth and efficiency in the competitive biotech industry.
Cost of Revenue Comparison: Pfizer Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Corcept Therapeutics Incorporated vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Wave Life Sciences Ltd. vs Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs Dyne Therapeutics, Inc.